Triplet or Quadruplet Regimen Utilization and Overall Survival in Patients Diagnosed With Multiple Myeloma Between 2017 and 2023

Documenti analoghi

• Lynozyfic (Linvoseltamab): A First‐in‐Class Off‐the‐Shelf T‐Cell Redirector for Refractory Multiple Myeloma
  di: Raza Ur Rehman
  Pubblicazione: (2025)
• Manifestations of Teclistamab‐Associated Uveitis
  di: Gabriel Castilho Barbosa, et al.
  Pubblicazione: (2025)
• Overall Survival of Patients With Pyruvate Kinase Deficiency in the UK: A Real‐World Study
  di: Patrick Foy, et al.
  Pubblicazione: (2025)
• High Fluorescent Lymphoid Cell Levels Assessed on Initial Blood Count in Newly Diagnosed Multiple Myeloma Carry Prognostic Significance
  di: Yasmine Aramon, et al.
  Pubblicazione: (2025)
• A Survey Study of Patient‐Physician Communication and Treatment Decision‐Making Preference at Treatment Initiation and After Disease Stabilization in Newly Diagnosed Multiple Myeloma
  di: Hitoshi Hanamoto, et al.
  Pubblicazione: (2026)